Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial
文献类型:期刊论文
作者 | Huang, Qidan1; Wu, Xiaohua2; Zhu, Jianqing3; Wang, Danqing4; Yang, Jiaxin5; Wang, Jing6; Wu, Lingying7; Liu, Ziling8; Gao, Yunong9; Wang, Danbo10 |
刊名 | GYNECOLOGIC ONCOLOGY |
出版日期 | 2021-08-01 |
卷号 | 162 |
ISSN号 | 0090-8258 |
资助项目 | GlaxoSmithKline |
WOS研究方向 | Oncology ; Obstetrics & Gynecology |
语种 | 英语 |
出版者 | ACADEMIC PRESS INC ELSEVIER SCIENCE |
WOS记录号 | WOS:000687070800027 |
资助机构 | GlaxoSmithKline |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/125099] |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China 2.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Beijing, Peoples R China 4.West China Second Univ Hosp, Chengdu, Peoples R China 5.Peking Union Med Coll Hosp, Beijing, Peoples R China 6.Hunan Canc Hosp, Changsha, Peoples R China 7.Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China 8.First Hosp Jilin Univ, Changchun, Peoples R China 9.Peking Univ Canc Hosp & Inst, Beijing, Peoples R China 10.China Med Univ, Canc Hosp, Shenyang, Liaoning, Peoples R China |
推荐引用方式 GB/T 7714 | Huang, Qidan,Wu, Xiaohua,Zhu, Jianqing,et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial[J]. GYNECOLOGIC ONCOLOGY,2021,162. |
APA | Huang, Qidan.,Wu, Xiaohua.,Zhu, Jianqing.,Wang, Danqing.,Yang, Jiaxin.,...&Dong, Juan.(2021).Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial.GYNECOLOGIC ONCOLOGY,162. |
MLA | Huang, Qidan,et al."Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial".GYNECOLOGIC ONCOLOGY 162(2021). |
入库方式: OAI收割
来源:合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。